Summary There is a pressing need to reduce the time and cost of developing new cytotoxic agents and to accurately identify clinically active agents at an early stage. In this study, the differential staining cytotoxicity (DiSC) assay was used to assess the efficacy of the novel antitumour cAMP analogue, 8-chloro-cAMP (8-Cl-cAMP) (and its metabolite 8-CI-adenosine) against 107 fresh specimens of human neoplastic and normal cells. Diagnoses included chronic and acute leukaemias, myeloma, non-Hodgkin's lymphoma (NHL) and miscellaneous solid tumours. The aim was to identify targets for subsequent phase 1, II and IlIl trials. 8-Cl-cAMP was tested at 4-985 gM, along with standard chemotherapeutic drugs. 8-Cl-cAMP and its metabolite caused no morphologically observable cell differentiation but induced dosedependent cytotoxicity. Compared with untreated patients, previously treated chronic lymphocytic leukaemia (CLL) patients showed no increase in ex vivo resistance to 8-Cl-cAMP (P = 0.878); minimal cross-resistance with other cytotoxic drugs was detected. Compared with normal cells (mean LC 9 = 1803 gM), 8-Cl-cAMP showed significant ex vivo activity against CLL (117.0 gM; P < 0.0001) and NHL (140.0 gM; P < 0.0001), of which eight were mantle cell NHL (84.7 gIM), and greatest activity against cells from patients with acute myeloid leukaemia (AML; mean LC 9 = 24.3 gm; in vitro therapeutic index 74-fold, P < 0.0001). Solid tumour specimens were comparatively resistant to 8-CI-cAMP. The results highlight the clinical potential of 8-Cl-cAMP, point to several new phase 1, II and IlIl trial possibilities and provide a rationale for the inclusion of ex vivo cytotoxic drug evaluation in the drug development process.
Drug development is a lengthy and expensive process, costing in excess of £100 million per licensed drug. A crucial decision point in the development of any new compound is whether to take it to clinical trial, a process requiring substantial investment. Usually, indications for a new cytotoxic compound are gleaned from cell line and xenograft studies; toxicology tests are then undertaken before the drug is entered into clinical trials (Carmichael, 1994) . The incorporation of a parallel series of ex vivo tests in different neoplasms at an early juncture ('ex vivo' is used to denote the determination of patient cellular response to drugs outside the body as a surrogate for treating the patient), using methodologies that predict well for subsequent patient response to known cytotoxic (Bosanquet, 1994) , could increase the likelihood that drugs progressed to trials will be clinically active.
Various ex vivo methods have been used to test new compounds (Nagoumey et al, 1993; Larsson et al, 1994; Martin et al, 1994; Hanauske et al, 1995) . In this paper we outline a development of this approach to drug evaluation whereby new agents are tested against both fresh human neoplastic cells (from haematological and solid tumours) and fresh human normal cells to identify promising targets for subsequent phase I, II and Ill trials. The experiments evaluate ex vivo cytotoxicity and the effect of patient pretreatment on these results, cross-resistance with other cytotoxic agents, ex vivo plus in vitro therapeutic indices and ex vivo phase II trials. Using 8-chloro-cAMP (8-Cl-cAMP), we have performed ex vivo evaluation concurrently with clinical phase I trials.
8-Cl-cAMP is a cyclic adenosine 3',5'-monophosphate (cAMP) analogue with novel properties, one of which is to down-regulate the Rla and up-regulate the RII subunits of cAMP-dependent protein kinase . RI is commonly overexpressed in malignancy (North et al, 1994) and RH is underexpressed; 8-Cl-cAMP can restore the normal balance of these proteins in vitro (Pinto et al, 1992; Lange-Carter et al, 1993; Rohlff et al, 1993a) .
In addition to its regulatory effects, 8-Cl-cAMP is cytotoxic to many cell types but, as has been suggested, only in the presence of phosphodiesterases (for instance, in fresh but not heat-inactivated serum; Borsellino et al, 1994) , which activate the drug to the metabolite 8-chloro-adenosine (8-Cl-adenosine) ( Van-LookerenCampagne et al, 1991; Taylor et al, 1992; Lange-Carter et al, 1993) . 8-Cl-adenosine is a cytotoxic species (Langeveld et al, 1992a) but, although it is not a direct inhibitor of cAMP-dependent protein kinases (Langeveld et al, 1992a) , it down-regulates RI and increases the R2/R1 subunit ratio.
8-Cl-cAMP has also been found to reverse doxorubicin resistance in HL-60 cells that exhibit the multidrug-resistant (MDR) phenotype but do not express the mdr-I gene product P-glycoprotein (Rholff et al, 1993b) . However 8-Cl-cAMP does not affect the doxorubicin sensitivity of MDR-expressing cell lines (Borsellino et al, 1994) , although it is able to down-regulate the expression of MDR (Glazer and Rohlff, 1994; Scala et al, 1995) .
Thus, 8-Cl-cAMP has a unique spectrum of anti-cancer properties, which are currently being investigated in phase I trials (Saunders et al, 1995; Tortora et al, 1995) . We undertook our ex vivo evaluation (using DiSC assay) concurrently with these trials to identify phase II disease targets and drug combinations (8-ClcAMP plus other cytotoxics) that would make good candidates for phase III trials.
The DiSC assay is one of a number of ex vivo drug response assays (Fruehauf and Bosanquet, 1993) , but it is the assay of choice for this type of drug evaluation because of its unique ability to selectively identify tumour cell drug response within a heterogeneous cell culture. Published correlations for the DiSC assay give an overall predictive accuracy of 83%, with a sensitivity of 94% and a specificity of 71% (Fruehauf and Bosanquet, 1993; Bosanquet, 1994) . The drug response information from test results can provide useful guidance in planning patient treatment (Tidefelt et al, 1989; Gazdar et al, 1990; Bosanquet, 1991; Weisenthal, 1991; Weisenthal and Kern, 1991; Fruehauf and Bosanquet, 1993; Bosanquet, 1994; Bosanquet et al, 1995) . This analysis and presentation of results represents a comprehensive overview of the action of 8-Cl-cAMP against fresh human tumour cells ex vivo. In particular, the analysis with 8-Cl-cAMP provides a number of clear pointers for its future clinical development. However, the general methodology is readily applicable to other new cytotoxic drugs and could result in time-saving and financial benefits by bridging the gap between preclinical and clinical studies.
MATERIALS AND METHODS DiSC assay
Specimen collection, tumour cell isolation and DiSC assay methodology were all performed using published methods (Bosanquet and Forskitt, 1989; Bosanquet, 1991; Bosanquet and Bell, 1996a) . Experiments were performed either in RPMI 1640 (Gibco) with 10% fresh (not heat-inactivated) fetal calf serum (Gibco, Paisley, UK) or in serum-free medium (Ultraculture, BioWhittaker, Wokingham, UK).
Briefly, 100 gl of cells at 8 x 105 ml-1 were incubated with drugs in 0.6-ml polypropylene tubes for 4 days in duplicate. A mixture of fast green and nigrosin dyes and fixed duck erythrocytes (as an internal standard) was added to the cell suspensions, followed by cytocentrifugation of cells onto microscope slides and counterstaining of the cells with a Romanowsky stain. LC90 values, i.e. the lowest 8-Cl-cAMP concentrations at which 90% of cells are killed relative to controls, were determined in drug-treated samples by LC90 evaluation (Bosanquet and Bell, 1996a) .
Preparations of mononuclear cells from blood and bone marrow and cells isolated from other sources sometimes contained normal cells. In these cases, normal and tumour cells were cultured together. Resulting slides were counted twice: once to obtain a tumour cell LC90, the second time to obtain a normal cell LC90
These results were used to determine the ex vivo therapeutic index as described below.
Drugs 8-Cl-cAMP (8-chloro-cyclic adenosine 3',5'-monophosphate, sodium salt; NSC 614491) was obtained already dissolved in 0.9 M sodium chloride at 3.8 mg ml-' (9.85 mM) as the i.v. infusion (Toa Nenryo Kogyo, Saitama-Ken, Japan); it is chemically stable in this vehicle (Cummings et al, 1994 Figure 2 confirm the cytotoxic equivalence of 8-ClcAMP in serum-containing medium and 8-Cl-adenosine in serumfree medium. Thus ex vivo results subsequently presented as 8-Cl-cAMP in the text and in Figures 3, 4 and 6 include some results from 8-Cl-adenosine in serum-free medium (7 out of 48 in Figures 3 and 4; 23 out of 115 including 3 out of 18 normals in Figure 6 ).
Data analysis
All LC 9 values were logarithmically transformed before the mean and s.d. values were calculated giving, unless otherwise stated, geometric mean x. geometric s.d. (Bosanquet and Bell, 1996b) . Specimens from eight patients yielded paired tumour and normal cell LC 9 values; from each of these, an ex vivo therapeutic index could be calculated:
Patient ex vivo therapeutic index = normal cell LC90 tumour cell LC90
A general therapeutic index could also be calculated using the mean of all normal cell results. This is graphed on the right hand yaxis of Figure Pearson correlation coefficients (r) were calculated on the logtransformed LC 9 values with pairwise missing-value treatment. Significance was calculated using Student's two-tailed t-test with Bonferroni correction.
Ex vivo cytotoxic drug evaluation
A synthesis of ex vivo experiments and data analysis provides a thorough overview of the drug's action against fresh human tumour cells. These experimental components include: 1. ex vivo cytotoxicity of the drug; 2. effect of patient pretreatment on ex vivo cytotoxicity; 3. cross-resistance of the new drug with known cytotoxic agents; 4. ex vivo phase II trials in various diagnoses; 5. cytotoxicity against normal human cells; 6. ex vivo (intra-patient) therapeutic index; 7. in vitro therapeutic index; 8. other drug-specific ex vivo experiments -for instance investigation of ex vivo differentiation with 8-Cl-cAMP.
RESULTS Specimens
One hundred and seven specimens from a variety of tumour types tested with 8-Cl-cAMP and/or 8-Cl-adenosine yielded tumour LC 9 values; eight of these yielded both normal and tumour LC90
values and 10 specimens yielded only normal cell LC 9 results. Thus, the results reported here are from 97 tumour specimens (Table 1) and 18 normal specimens (Table 2) . A further series of 27 specimens of CLL were also tested with 8-Cl-cAMP in serumfree medium, yielding data for Figures 1 and 2; but as the drug is less active under these conditions, these results were excluded from further analysis. Cells were carefully assessed after the 4-day incubation to ascertain whether differentiation had been induced ex vivo in AML specimens, in which it had been reported with other methodologies (Pinto et al, 1992 Figure 3 . The results
show that treatment did not induce ex vivo resistance to 8-Cl-cAMP (P = 0.878). Similar results were found with other leukaemic specimens of various diagnoses, suggesting that lack of induced resistance to 8-Cl-cAMP is not disease specific (Figure 6 ). Figure  4 . No drug showed marked cross-resistance with 8-Cl-cAMP. The largest correlation coefficients were seen with the anthracyclines doxorubicin (r = 0.525, P < 0.01) and epirubicin (r = 0.500, P < 0.01). Of particular interest is the almost complete lack of cross-resistance with pentostatin and with cladribine and fludarabine, two purine analogues that have similar structures ( Figure 5 ) and known clinical activity against CLL, AML and NHL. Other tumour types may exhibit different cross-resistance profiles. In Figure 2 , the difference between the cytotoxicity of 8-ClcAMP and 8-Cl-adenosine to CLL is presented, both in serum and in serum-free media. 8-Cl-adenosine is not significantly more toxic than 8-Cl-cAMP in RPMI 1640 containing 10% fetal bovine serum (mean LC, values 109.7 gM and 77.6 gM respectively, P = 0.484; six paired experiments, P = 0.205) and the correlation coefficient (r) between 8-Cl-cAMP and 8-Cl-adenosine was 0.966 (n = 6 CLL specimens, P = 0.002). However the paired results in serum-free medium gave a mean difference in LC 9 of 35.9-fold (mean LC 9 values for 8-Cl-cAMP and 8-Cl-adenosine 3942 gM and 110 ,UM respectively, P < 0.0001). Subsequent data include results from 8-Cl-cAMP in serum and 8-Cl-adenosine in serumfree medium.
Ex vivo phase 11 trials
In Figure 6, Figure 6 ). These findings in AML are particularly interesting as many of the patients had previously received cytotoxic chemotherapy (for details, see Figure 6 legend). The most resistant AML specimen was from a pretreated patient with primary refractory disease (FAB-type Ml).
Patient ex vivo therapeutic index
The eight sets of paired normal and tumour cell data gave ex vivo (intra-patient) therapeutic indices (TI) of 2.5-100 (mean Normal cell LCgo values are from AML (El), myeloma (c), mantle cell lymphoma (V), other NHL (A\), T-PLL (tv), benign lymph node (*) and solid tumours (-) of breast, head and neck, melanoma, pancreas, prostate, uterus and unknown primary. PR-AML, primary refractory AML-M1. For abbreviations see Table 1 . Dotted lines link results from co-incubated normal (lymphoid cells and neutrophils) and tumour cells (myeloblasts) from three individual AML patients. Open symbols, untreated; filled symbols, patient previously treated. Details of previous chemotherapy administered to these patients are as follows: seven AML patients were previously treated with cytarabine-containing regimens (primarily ADE or DAT) and five of these had also received idarubicin, amsacrine or both; one AML patient was initially diagnosed as NHL before immunocytochemical analysis and had received chlorambucil only; pretreatment details of a further AML patient are unknown; 21 CLL patients had received a median of two chemotherapy regimens: chlorambucil (21/21), cyclophosphamide [chiefly cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP); 9/21], anthracycline (doxorubicin, epirubicin or mitoxantrone; 11/21); antimetabolite (chiefly fludarabine; 11/21); 12 NHL patients had received a median of two regimens: chlorambucil, CHOP or COP (no doxorubicin) (12/12), anthracycline (chiefly doxorubicin; 10/12), fludarabine (5/12), ± other treatment (carboplatin, cisplatin, etoposide, bleomycin, high-dose dexamethasone, radiotherapy; 6/12). The relatively sensitive ALL patient had received CHOP, methotrexate, vincristine, high-dose cytarabine, amsacrine, doxorubicin and fludarabine. The T-ALL patient had been treated according to the UKALL XII trial. The T-PLL patient had received CAMPATH and prednisolone. The HCL patient had received chlorambucil followed by CHOP. The mAL patient was heavily pretreated with three AML-based regimens and then ALL-based chemotherapy. The two myeloma patients had received two and four drug regimens respectively. The relatively sensitive SCLC patient had received epirubicin plus ifosfamide followed by cisplatin plus etoposide TI = 10.2 x. 1.52; paired t-test, P = 0.0009). The three paired AML LC 9 values in Figure 4 had a mean TI of 15.4 (paired t-test, P = 0.0073). investigated at an earlier stage to determine which would be most relevant to take to the clinic, i.e. the most active against the target tumour in vitro, least cross-resistant with known cytotoxics and with the best ex vivo and in vitro therapeutic indices. In conjunction with other methods of screening for new cytotoxic agents (Weisenthal, 1992; Carmichael, 1994; Boyd and Paull, 1995) , this methodology could aid decision-making in cytotoxic drug development.
DISCUSSION
The results presented here are somewhat different from those generated using the colony-forming (Martin et al, 1994; Hanauske et al, 1995) and fluorometric microculture cytotoxicity (FMC) assays (Larsson et al, 1994) to screen for new anti-cancer agents; we have measured one-log cell kill (as opposed to 50% or 0.3 log) (Nagourney et al, 1993; Larsson et al, 1994; Martin et al, 1994; Hanauske et al, 1995) on all morphologically identifiable tumour cells [rather than .0.004% of cells that form colonies (Martin et al, 1994; Hanauske et al, 1995) ]. We have also determined the cytotoxic effect on normal and leukaemic as well as solid tumour cells, in a 4-day test (rather than 14-28 days). As such, we consider the strategy presented here provides a significant step forward in the development of ex vivo cytotoxic drug evaluation.
These results with 8-Cl-cAMP have highlighted this drug's potential as an effective anti-cancer drug in a number of ways. 8-Cl-cAMP has recently undergone two phase I trials using continuous, low-dose infusion (Saunders et al, 1995; Tortora et al, 1995) with the aim of inducing terminal differentiation of tumour cells through the up-regulation of the RII-regulatory subunit of cAMPdependent protein kinase . The data presented here suggest cytotoxicity, not differentiation, as the mode of action in our system, even at the lowest concentration tested (3.85 gM). A similar lack of differentiation was observed with glioma cell lines (Langerveld et al, 1992b) . Thus, the ex vivo mode of tumour cell kill by 8-Cl-cAMP is probably similar to that of other cytotoxic agents, suggesting that i.v. bolus administration, with the aim of inducing cytotoxicity rather than differentiation, should be investigated.
In this work, we have required higher concentrations ex vivo than plasma concentrations measured after continuous i.v. infusion in phase I trials. Two factors may account for this. Firstly, the rationale for the dose intensities and regimens of 8-Cl-cAMP in these phase I trials has been based on its capacity as a modulator of cAMP -dependent protein kinases. Low-dose continuous i.v. infusion (10 days of infusion every 3 weeks at 0.2 or 0.25 gg kg-' h-1; Tortora et al, 1995) has therefore been one chosen mode of administration, and this has yielded plasma concentrations of approximately 2-5 gM. Again, as we have measured cytotoxicity rather than differentiation, higher ex vivo concentrations are to be expected. Areas under the time x concentration curve may well be similar.
Secondly, we expect mean ex vivo LC90 concentrations in general to be of a similar order to i.v. bolus injection peak plasma concentrations (Fruehauf and Bosanquet, 1993) . Peak plasma concentrations by this administration are typically 30-to 100-fold greater than those obtained for the same drug by continuous infusion. (For instance, for carboplatin compare Allsopp and Sewell, 1995 with Harland et al, 1984 and Reece et al, 1987 ) Thus, there is no obvious discrepancy between the LC90 values presented in this work and drug levels measured in vivo.
An excellent ex vivo therapeutic index was found in CLL, NHL and particularly AML, suggesting that they are strong candidates for early phase II trials of 8-Cl-cAMP. The identification of sensitivity in mantle cell NHL is of special interest as this is a particularly resistant disease (Vandenberghe, 1994 ).
The moderate cross-resistance between 8-Cl-cAMP and doxorubicin sensitivity is unexpected, but it confirms a report using cell lines that demonstrated hypersensitivity both to topoisomerase II inhibitors and 8-Cl-cAMP (North et al, 1994) , suggesting some interaction between the two cytotoxic pathways.
The relative lack of cross-resistance with other cytotoxic drugs (Figure 4) gives indications for phase III combinations worthy of consideration, in particular with the alkylating agents (including cisplatin; Nishio et al, 1992) and vinca alkaloids. Even the antimetabolites with very similar structures, i.e. fludarabine, cladribine ( Figure 5 ) and pentostatin, are essentially non-crossresistant with 8-Cl-cAMP (Figure 4) . The role of 8-Cl-cAMP in overcoming multiple drug resistance by down-regulating mdr-1 expression (Yokozaki et al, 1993; Glazer and Rohlff, 1994; Scala et al, 1995) provides a rationale for its use in combination with drugs such as the anthracyclines. Further work, exploring 8-ClcAMP in combination with other drugs and cross-resistance in other tumour types could be usefully undertaken ex vivo.
Prior administration of various chemotherapeutic agents induced no discernible ex vivo resistance to 8-Cl-cAMP (Figure 3 , also Figure 6 ) in contrast to many other drugs tested in these and other CLL specimens. For instance, highly significant increases in treatment-induced resistance were seen with other antimetabolites ex vivo, including cytarabine, fludarabine, cladribine and pentostatin (Bosanquet and Bell, 1996b) . This suggests that 8-ClcAMP's mode of action is unique among cytotoxic drugs despite the similarity of structure (Figure 5) . Work with paired cell lines (sensitive/resistant to doxorubicin or radiation) supports this proposition, with no difference in 8-Cl-cAMP cytotoxicity between resistant and wild-type cell lines observed (Borsellino et al, 1994; Buraczewska et al, 1994) . After development of clinical drug resistance to initial therapy, a patient's tumour might still be sensitive to 8-Cl-cAMP, especially if the drug is shown to be active ex vivo. Indeed, some patients are still very sensitive to 8-ClcAMP even after multiple chemotherapy (Figure 6 ).
In conclusion, the general methodology of ex vivo cytotoxic drug evaluation, undertaken concurrently with phase I trials in vivo, could enable targets for phase II trials to be identified more rapidly. This should reduce the time and cost of licensing a new cytotoxic drug and thereby benefit both pharmaceutical companies and patients.
For 8-Cl-cAMP in particular, the lack of induction of resistance by previous cytotoxic therapy, the lack of marked cross-resistance, the good ex vivo therapeutic index and novel mode of action all combine to suggest that 8-Cl-cAMP is an exciting new cytotoxic agent that could have a considerable role in the future treatment of neoplastic disease. The results suggest: a new phase I trial with a schedule that will induce cytotoxicity as well as inhibition; phase II trials in CLL, (mantle cell) NHL and particularly AML; and combinations of 8-Cl-cAMP with other cytotoxic agents for both ex vivo and clinical phase III investigation.
